Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist marketed as Ozempic, Wegovy, and Rybelsus, does not typically appear on standard blood tests ordered during routine medical care
This suggests that the application of any topical treatment may induce a localized inflammatory reaction in the initial phase
use sunscreen to protect healing skin
Yet, the FDA cautions that the safety and effectiveness of combining a GLP-1 drug with additional ingredients, such as cyanocobalamin (Vitamin B-12) and pyridoxine (Vitamin B-6), have not been established
Member of the Latinoamerican Board of Eli Lilly and Sanofi Aventis Member of the National Board of the following laboratories: Novo Nordisk, Novartis, GlaxoSmithKlein Sanofi, Aventis, Boheringer Ingelheim, Bristol Myers, Astra Zeneca Main investigator of Protocols from: Eli Lilly, Novo Nordisk, Novartis, GlaxoSmithKlein, Takeda, PPDF, Pfizer, Merck Sharp Dome, Amgen, Roche, Minimed, Quintiles Speakers of the former laboratories